Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,406 across all filing types
Latest filing 2016-07-04 Report Publication Anno…
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
European analyst and investor event in London on July 13
Report Publication Announcement Classification · 99% confidence The document is a press release dated July 4, 2016, announcing that Innate Pharma will host an event for analysts and investors in London on July 13th, 2016, to discuss corporate strategy, programs, and R&D. This announcement pertains to an upcoming investor/analyst briefing, which is a form of communication directed at investors regarding company strategy and pipeline updates. This aligns best with the 'Investor Presentation' (IP) category, as it is an announcement about a detailed presentation event, even though the presentation itself is in the future. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a dividend notice (DIV). Since it is an announcement about a specific event where strategy and science will be discussed in detail, IP is the most appropriate fit over a general Regulatory Filing (RNS).
2016-07-04 English
Présentation pour les analystes et investisseurs européens le 13/07
Report Publication Announcement Classification · 99% confidence The document is a press release dated July 4, 2016, announcing that Innate Pharma will host an event for European analysts and investors in London on July 13, 2016, to discuss strategy, pipeline, science, and R&D. The content focuses entirely on scheduling and describing this upcoming presentation/event for investors. This aligns perfectly with the definition of an Investor Presentation (IP), which involves detailed presentations for investors focusing on financials, strategy, and market position, even if the announcement itself is about the event rather than the presentation slides themselves. It is not a formal regulatory filing like a 10-K or an ER, nor is it a transcript of a call (CT). Since it is announcing a detailed presentation event, IP is the most appropriate classification over a general RPA or RNS.
2016-07-04 French
ASCO 2016 : Presentation du protocole de l'essai clinique de Phase I
Investor Presentation Classification · 95% confidence The document is a press release dated June 5, 2016, announcing the presentation of a Phase I clinical trial protocol for IPH4102 at the ASCO 2016 annual congress. It details the study design, objectives, and provides background information on the drug and the company (Innate Pharma). This type of announcement, focusing on clinical trial updates, scientific presentations, or pipeline progress, is typically classified as an Investor Presentation (IP) if it were a deck, or often falls under general regulatory/investor communications. Since it is a formal press release detailing scientific progress and future data expectations, and it is not a formal financial report (10-K, IR, ER), nor a specific management change (MANG) or dividend notice (DIV), it best fits the Investor Presentation (IP) category, as it is designed to inform investors about R&D milestones. It is not a Report Publication Announcement (RPA) because it is the substantive news itself, not just an announcement that a report is available.
2016-06-05 French
asco 2016: Phase I study protocol investigating IPH4102 in CTCL
Regulatory Filings Classification · 95% confidence The document is a press release dated June 5, 2016, from Innate Pharma SA. It announces that a protocol for a Phase I study of IPH4102 was discussed at the 2016 ASCO annual meeting. The text details the study design, objectives, and provides background on the drug and the company. This format—a formal announcement of clinical trial progress or presentation at a conference, often including forward-looking statements and contact information—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR) or a transcript (CT), and it specifically announces clinical/research progress, it fits best as a general announcement. Given the context of providing updates on company activities and research milestones, and lacking specific financial reporting headers, it aligns most closely with a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were tied to a reporting period, but it reads more like a scientific update announcement. Since it is a press release announcing scientific progress and not a formal financial statement, RNS is the most appropriate general category for non-standard announcements.
2016-06-05 English
PR in English
Share Issue/Capital Change Classification · 95% confidence The document explicitly states its purpose: to release the 'Total number of shares outstanding as well as its voting rights as at May 30, 2016,' citing requirements from the French Commercial Code and the AMF (Autorité des Marchés Financiers). This type of mandatory disclosure regarding the total number of shares and voting rights is a specific regulatory filing requirement, often related to changes in capital structure or major shareholdings, but it is a distinct, recurring notification. It is not an Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). While it relates to share capital, it is a specific regulatory count update. Given the options, this type of mandatory disclosure, which is not a full financial report or a specific insider trade report, fits best under the general 'Regulatory Filings' (RNS) category, as it is a specific regulatory notification required by the market authority (AMF) that doesn't align perfectly with the other specialized codes like DIRS (Director's Dealing) or SHA (Share Issue/Capital Change - which usually implies an offering or split). Since it is a formal, required disclosure to the market authority about the current share structure, RNS is the most appropriate fallback for a specific regulatory count update not covered elsewhere.
2016-06-03 English
CP en français
AGM Information Classification · 99% confidence The document is titled "RÉSULTATS DE L'ASSEMBLÉE GÉNÉRALE MIXTE DU 2 JUIN 2016" (Results of the Mixed General Meeting of June 2, 2016) and explicitly details the voting results and quorum achieved during the shareholder meeting. This directly corresponds to the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). Although it mentions the availability of the 2015 Annual Report and Reference Document, the primary content and title focus on the AGM voting outcomes.
2016-06-03 French

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.